术前化疗后切除的高危胃及胃食管结合部癌(ypN+和/或R1)辅助免疫治疗:欧洲癌症研究与治疗组织(EORTC)1707 VESTIGE研究
VESTIGE是一项国际多中心开放标签随机II期试验,评估纳武利尤单抗联合伊匹木单抗对比辅助化疗在高危胃食管腺癌(ypN+和/或R1)中的疗效。因无效提前终止,纳武利尤单抗联合伊匹木单抗组中位无病生存期11.4个月,化疗组20.8个月,风险比1.55,未改善无病生存。
要点
- 纳武利尤单抗联合伊匹木单抗组中位无病生存期11.4个月,化疗组20.8个月,HR 1.55。
- 12个月无病生存率分别为47.1%和64.0%。
- 独立数据监查委员会因无效建议停止入组,未发现毒性担忧或超额早期停药。
核心结论
- 在新辅助化疗和手术后ypN+和/或R1胃食管腺癌患者中,纳武利尤单抗联合伊匹木单抗对比化疗未改善无病生存期。
研究设计与样本
- VESTIGE为学术性国际多中心开放标签随机II期试验,评估辅助纳武利尤单抗联合伊匹木单抗对比化疗在高危胃食管腺癌中的疗效。
- 患者按1:1随机接受标准辅助化疗(与术前化疗方案相同)或纳武利尤单抗3 mg/kg静脉注射每2周联合伊匹木单抗1 mg/kg静脉注射每6周,共1年。
- 关键纳入标准为新辅助化疗加手术后ypN+和/或R1状态。
- 主要终点为意向治疗人群的无病生存期;次要终点包括总生存期、局部区域和远处失败率以及根据美国国家癌症研究所不良事件通用术语标准v5.0的安全性。
主要发现
- 独立数据监查委员会于2022年6月审查了计划240例患者中189例的数据,因无效建议停止招募。
- 最终分析时,195例患者(纳武利尤单抗联合伊匹木单抗组98例,化疗组97例)的中位随访时间为25.3个月。
- 纳武利尤单抗联合伊匹木单抗组中位无病生存期为11.4个月(95%CI 8.4-16.8个月),化疗组为20.8个月(95%CI 15.0-29.9个月),风险比1.55(95%CI 1.07-2.25,单侧P=0.99)。
- 12个月无病生存率分别为47.1%和64.0%。
- 未发现毒性担忧或超额早期停药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer and residual pathological disease following chemoradiation and surgery. Immune checkpoint inhibition has shown efficacy in advanced gastro-oesophageal cancer. We hypothesised that nivolumab/ipilimumab would be more effective than adjuvant chemotherapy in high-risk (ypN+ and/or R1) patients with gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and resection. PATIENTS AND METHODS: VESTIGE was an academic international, multicentre, open-label, randomised phase II trial evaluating the efficacy of adjuvant nivolumab/ipilimumab versus chemotherapy in gastro-oesophageal adenocarcinoma at high risk of recurrence. Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intravenously (i.v.) every 2 weeks plus ipilimumab 1 mg/kg i.v. every 6 weeks for 1 year. Key inclusion criteria included ypN+ and/or R1 status after neoadjuvant chemotherapy plus surgery. The primary endpoint was disease-free survival in the intent-to-treat population. Secondary endpoints included overall survival, locoregional and distant failure rates, and safety according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. RESULTS: The independent Data Monitoring Committee reviewed data from 189 of the planned 240 patients in June 2022 and recommended stopping recruitment due to futility. At the time of final analysis, median follow-up was 25.3 months for 195 patients (98 nivolumab/ipilimumab and 97 chemotherapy). Median disease-free survival for the nivolumab/ipilimumab group was 11.4 months [95% confidence interval (CI) 8.4-16.8 months] versus 20.8 months (95% CI 15.0-29.9 months) for the chemotherapy group, hazard ratio 1.55 (95% CI 1.07-2.25, one-sided P = 0.99). The 12-month disease-free survival rates were 47.1% and 64.0%, respectively. There were no toxicity concerns or excess early discontinuations. CONCLUSION: Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.
引用
- Lordick F, Mauer ME, Stocker G, et al. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Ann Oncol. 2024. PMID: 39542422. doi:10.1016/j.annonc.2024.10.829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。